Workflow
Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M
Biodexa Pharmaceuticals PLCBiodexa Pharmaceuticals PLC(US:BDRX) GlobeNewswire News Room·2025-05-22 20:30

May 22, 2025 Biodexa Announces Award of Additional 3.0MGrantfromCPRITtoSupportRegistrationaleRapaPhase3PrograminFAPBringsTotalCPRITGrantFundingforeRapaPhase3Programto3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to 20.0M Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced its collaboration partner, Rapamycin Holdings, Inc. d/b/a Emtora Biosciences (“Em ...